Mass spectrometry‐based characterization of histones in clinical samples: applications, progress, and challenges
Open Access
- 8 January 2021
- journal article
- review article
- Published by Wiley in The FEBS Journal
- Vol. 289 (5) , 1191-1213
Abstract
In the last 15 years, increasing evidence linking epigenetics to various aspects of cancer biology has prompted the investigation of histone post‐translational modifications (PTMs) and histone variants in the context of clinical samples. The studies performed so far demonstrated the potential of this type of investigations for the discovery of both potential epigenetic biomarkers for patient stratification and novel epigenetic mechanisms potentially targetable for cancer therapy. Although traditionally the analysis of histones in clinical samples was performed through antibody‐based methods, mass spectrometry (MS) has emerged as a more powerful tool for the unbiased, comprehensive, and quantitative investigation of histone PTMs and variants. MS has been extensively used for the analysis of epigenetic marks in cell lines and animal tissue and, thanks to recent technological advances, is now ready to be applied also to clinical samples. In this review, we will provide an overview on the quantitative MS‐based analysis of histones, their PTMs and their variants in cancer clinical samples, highlighting current achievements and future perspectives for this novel field of research. Among the different MS‐based approaches currently available for histone PTM profiling, we will focus on the ‘bottom‐up’ strategy, namely the analysis of short proteolytic peptides, as it has been already successfully employed for the analysis of clinical samples.Keywords
Funding Information
- Ministero della Salute (GR‐2016‐02361522)
- Associazione Italiana per la Ricerca sul Cancro (IG‐2018‐21834)
- Horizon 2020 Framework Programme (823839)
This publication has 172 references indexed in Scilit:
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomasNature Genetics, 2012
- Regulation of chromatin by histone modificationsCell Research, 2011
- SILAC-based proteomic analysis to dissect the “histone modification signature” of human breast cancer cellsAmino Acids, 2010
- Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and CarcinomaDigestive Diseases and Sciences, 2008
- Global Changes in and Characterization of Specific Sites of Phosphorylation in Mouse and Human Histone H1 Isoforms upon CDK Inhibitor Treatment Using Mass SpectrometryJournal of Proteome Research, 2008
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancersMolecular Carcinogenesis, 2008
- Chromatin Modifications and Their FunctionCell, 2007
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- The language of covalent histone modificationsNature, 2000